PPIDT00229
Drug Information
| Name | Golimumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06674 |
| Type | biotech |
| Indication | Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA)[L16626], (ii) in patients 2 years old and above with active psoriatic arthritis (PsA)[L16626], (iii) as a single agent in patients with active ankylosing spondylitis (AS) or in combination with methotrexate[L16631], and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.[L16631] It is also indicated (v) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.[L16626] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
50 mg/0.5ml
|
| Injection, solution | Parenteral; Subcutaneous |
100 MG
|
| Injection, solution | Parenteral; Subcutaneous |
45 MG/0.45ML
|
| Injection, solution | Parenteral; Subcutaneous |
50 MG
|
| Injection, solution | Subcutaneous |
100 mg
|
| Injection, solution | Subcutaneous |
100 mg/1mL
|
| Injection, solution | Subcutaneous |
50 mg/0.5mL
|
| Solution | Subcutaneous |
100 mg / 1.0 mL
|
| Solution | Subcutaneous |
50 mg / 0.5 mL
|
| Solution | Subcutaneous |
50.000 mg
|
| Injection, solution | Parenteral |
100 MG
|
| Injection, solution | Parenteral |
50 MG
|
| Injection, solution | — |
50 mg
|
| Injection | — |
50 mg/5ml
|
| Injection | — |
50 mg
|
| Solution | Intravenous |
50 mg/4mL
|
| Solution | Intravenous |
50 mg / 4.0 mL
|
| Injection, solution | Intravenous |
12.5 mg/1ml
|
| Injection, solution | Subcutaneous |
50 mg
|
| Solution | — |
50 mg/0.5ml
|
| Injection, solution | Subcutaneous |
45 mg/0.45ml
|
| Solution | Intravenous |
12.5 mg/1ml
|
| Injection, solution | Subcutaneous |
100 mg/1.0ml
|
| Solution | Intravenous |
50 mg
|
| Solution | Intravenous |
5000000 mg
|
| Solution | Subcutaneous |
5000000 mg
|